The present invention relates to a topical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R1 is ethyl or propyl, preferably propyl; R2 is methyl or ethyl, preferably methyl; R3 is ethyl or propyl, preferably propyl; X is N or CH, preferably CH; n is 1 or 2, preferably n=1; as well as to the uses of said topical compositions for the treatment of diseases or disorders mediated by PDE5 activity and / or NO related
endothelial dysfunction, preferably of a
disease or disorder of the
skin mediated by PDE5 activity and / or NO related
endothelial dysfunction, in a subject, preferably in a human, and particularly, for the treatment of ischemic
skin ulcers, digital ulcers (DU) in systemic sclerosis,
diabetic foot ulcer,
leg ulcer, ischemic arterial ulcers, livedoid vasculopathy, Martorell hypertensive ischemic
leg ulcer, thromboangiititis obliteragans (Buerger's
disease), sickle
cell leg ulcer, all of the foregoing preferably for
wound healing, further preferably for
chronic wound healing.